Birt-Hogg-Dube syndrome: metalloproteinase activity and response to doxycycline by Pimenta, Suzana Pinheiro et al.
  Universidade de São Paulo
 
2012
 
Birt-Hogg-Dube syndrome: metalloproteinase
activity and response to doxycycline
 
 
CLINICS, SÃO PAULO, v. 67, n. 12, pp. 1501-1504, DEC, 2012
http://www.producao.usp.br/handle/BDPI/42674
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Cardio-Pneumologia - FM/MCP Artigos e Materiais de Revistas Científicas - FM/MPT
CASE REPORT
Birt-Hogg-Dube´ syndrome: metalloproteinase
activity and response to doxycycline
Suzana Pinheiro Pimenta,I Bruno Guedes Baldi,I Ellen Caroline Toledo do Nascimento,II Thais Mauad,II
Ronaldo Adib Kairalla,I Carlos Roberto Ribeiro CarvalhoI
I Faculdade de Medicina da Universidade de Sa˜o Paulo, Heart Institute (InCor), Pulmonary Division, Sa˜o Paulo/SP, Brazil. II Faculdade de Medicina da
Universidade de Sa˜o Paulo, Department of Pathology, Sa˜o Paulo/SP, Brazil.
Email: spp3847@yahoo.com.br
Tel.: 55 11 8232-6007
INTRODUCTION
Birt-Hogg-Dube´ syndrome (BHDS) is a rare, inherited
autosomal-dominant genodermatosis caused by mutations
in the folliculin gene (FLCN), which is located within the
chromosomal band 17p11.2 (1). Patients with BHDS are
prone to fibrofolliculomas, trichodiscomas, and acrochor-
dons on the face, neck, and upper trunk; renal tumors;
pulmonary cysts; and spontaneous pneumothorax (2-4).
The pathogenesis of lung cyst formation and pneu-
mothorax remains unclear, but studies have shown that
folliculin is strongly expressed in lung fibroblasts and
macrophages. Folliculin mutations may alter cytokines and
proteases, which are important in maintaining extracellular
matrix (ECM) integrity, leading to an inflammatory re-
sponse and matrix degradation with subsequent remodeling
(5,6).
The pulmonary architecture depends on interactions
between collagen and elastin fibers in the ECM, which
maintain alveoli wall integrity (7). The overexpression of
metalloproteinases (MMPs), regardless of whether they are
associated with the suppression of tissue inhibitors of
metalloproteinases (TIMPs), leads to matrix breakdown,
tissue destruction and cystic lesions (7,8).
Because there is currently no treatment for BHDS, we
decided to describe our experience treating one BHDS
patient with doxycycline, which is an MMP inhibitor (9) that
has been previously used to treat cystic lung disease (10).
Case Description
A 44-year-old female non-smoker complained of mild
dyspnea upon exertion in 2004 and presented with a spon-
taneous pneumothorax in 2005. Chest computed tomogra-
phy (CT) demonstrated bilateral thin-walled cystic lesions
(Figure 1). Pulmonary functional tests (PFTs) showed normal
carbon monoxide diffusion capacity (DLCO=81% of the
predicted value), lung volume, and expiratory flow rate,
but an increased residual volume (RV) and total lung
capacity (TLC) ratio (RV/TLC=0.45) were found, as shown
in Table 1. An abdominal CT was also normal. A lung biopsy
and pleurodesis by videothoracoscopy were performed, and
the patient was diagnosed with lymphangioleiomyomatosis
(LAM). She was referred to our institution in 2006 to
participate in a doxycycline treatment protocol.
All patients with a diagnosis of LAM who were enrolled
in this protocol were submitted to lung function evaluation
and ELISA-based quantitative serum and urinary MMP-2
and -9 analysis (R&D Systems; Minneapolis, MN, USA)
before and after doxycycline treatment (11).
After six months of receiving doxycycline (100 mg/day),
the patient noticed resolution of the exertional dyspnea and
improvement in exercise tolerance. After treatment, DLCO
and forced vital capacity (FVC) showed increases from 16.8
to 19.7 mL/min/mmHg and 2.87 to 3.12 L, respectively.
The forced expiratory volume in the first second (FEV1), RV
and RV/TLC values pre- and post-doxycycline were,
respectively, 2.36 and 2.35 L, 2.23 and 1.51 L, and 0.45 and
0.32 (Table 1).
The MMP blockade induced by doxycycline was effective,
resulting in a reduction in serum MMP-9 levels from 143 to
36 ng/mL, and urinary levels of MMP-9 became untrace-
able (55 pg/mL before doxycycline). MMP-2 levels were not
detectable before or after treatment.
During follow-up, the patient presented with soft and
pedunculated papules on her neck and upper thorax. The
biopsy of these lesions was compatible with acrochordons.
The patient’s family medical history also revealed other
cases of cystic lung disease (Figure 2).
The lung biopsy specimen was reviewed in 2007.
Histological analysis of the lung tissue revealed several
cystic areas with an emphysematous aspect in the lung
parenchyma, mostly in the subpleural region. Cyst walls
were formed by collapsed alveolar parenchyma or slightly
thickened pleural tissue. LAM cells were not observed in the
cyst walls, and monoclonal antibody HMB-45 (human
melanoma black-45), S100 protein and alpha smooth muscle
actin were also not observed (Figure 3).
Based on the family history, the presence of cutaneous
lesions (acrochordons), the CT findings and the lung
histological review, the diagnosis of BHDS was established.
The positive response to doxycycline treatment, which
had never been demonstrated in BHDS, and the association
between the loss-of-function mutation in folliculin and
pulmonary extracellular matrix degradation (6), led us to
evaluate MMP behavior in lung tissue.
Immunohistochemical analysis in the patient’s lung tissue
revealed a large number of MMP-9-positive cells, mostly
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macrophages and neutrophils, in the cyst wall, whereas the
adjacent lung parenchyma presented scattered MMP-9-
positive cells along the alveolar walls (figure 3). MMP-2
staining showed scattered positive inflammatory cells in the
lung parenchyma with no specific cyst staining.
During the subsequent months, the patient developed
gastric intolerance symptoms, leading to the interruption of
doxycycline therapy. Spirometry performed 18 months after
doxycycline interruption revealed a decrease in lung
volume and expiratory flow rates (Table 1) with worsening
of the pulmonary symptoms.
DISCUSSION
In a non-smoking female who develops spontaneous
pneumothorax and presents with cysts in the thoracic high
resolution CT, LAM is a strong diagnostic possibility.
However, other cystic lung disorders, such as BHDS, may
have the same presentation.
In the past several years, lung cyst pathogenesis has been
widely studied in pulmonary cystic diseases, such as LAM,
Langerhans cell histiocytosis (LCH) and cystic lung light
chain deposition disease (CL-LCDD). MMPs appear to have
an important role in the pathogenesis of cyst formation
(8,12-14). These proteins belong to a family of proteolytic
enzymes and are classified according to their specific
substrates into gelatinases (MMP-2 and -9), interstitial
collagenases (MMP-1, -8 and -13) and stromelysins (MMP-
3, -7 and -10). These enzymes are mainly responsible for
ECM remodeling, but they also affect cell migration,
angiogenesis and pulmonary immunity (7,15,16).
In LAM, lung cyst development is affected by MMP-2
and -9 upregulation in LAM cells (abnormal smooth
muscle-like cells) rather than in vascular and bronchiolar
smooth muscle cell (14,17). High serum MMP-9 levels are
also present in the blood of patients with LAM (17). Zhe
et al. described the downregulation of TIMPs, especially
TIMP-3, followed by MMP-2 and -14 overexpression, in
LAM cells (18).
LCH is characterized by irregularly dilated alveolar
spaces and degraded elastic fibers that are surrounded by
granulomatous lesions. An immunohistochemical study
showed MMP-2 expression in the epithelial basement
membranes of these damaged areas and collagen type IV
impairment (12,19).
Figure 1 - High-resolution chest CT. A) A CT scan showing thin-walled, air-filled cystic lesions, including one dominant cyst (665 cm).
B) In addition to the cystic lesions, posterior pleural thickening due to previous pleurodesis is observed on the right side.
Table 1 - Pulmonary function tests performed before and during doxycycline treatment and 18 months after doxycycline
interruption.
Before doxy During doxy After doxy
Pulmonary function variables 3 months 6 months 18 months
FVC - L (% pred) 2.87 (82) 3.03 (83) 3.12 (85) 2.33 (70)
FEV1 - L (% pred) 2.36 (87) 2.34 (79) 2.35 (80) 2.21 (80)
FEV1/ FVC 0.82 0.77 0.76 0.95
TLC - L (% pred) 4.87 (94) x 4.74 (93) x
RV/TLC (% pred) 0.45 (137) x 0.32 (97) x
DLco - mL/min/mmHg (% pred) 16.84 (81) x 19.7 (80) x
FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; TLC: total lung capacity; RV: residual volume; DLCO: carbon monoxide
diffusion capacity.
Figure 2 - Pedigree of the family. Square =male member,
circle = female member; solid symbol = pneumothorax, open
symbol =no pneumothorax; slash through symbol= cystic lesions
on lung CT; * our patient.
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Pulmonary involvement is especially rare in light chain
deposition disease (LCDD), which is a systemic disorder
characterized by diffuse monoclonal nonamyloid light chain
deposits. There are two types of lung impairment: nodular
and CL-LCDD. In CL-LCDD, giant macrophagic cells
located around light chain deposits express MMP-2, -9,
and -14, which can degrade the elastic network (8,20).
BHDS, an inherited and rare disorder caused by an FLCN
mutation, presents with dermatologic and pulmonary
involvement and usually manifests during the third or
fourth decade of life (2,3). Patients with BHDS have an
increased risk of renal cell carcinoma, colorectal neoplasia
(3,21) and parotid oncocytomas (22). Abnormal pleuropul-
monary findings include lung cysts, pleural blebs and
spontaneous pneumothorax (4). Histopathological studies
are very limited, especially studies investigating cystic lung
pathogenesis. Butnor and Guinee (23) described nonspecific
features in the lung biopsies of two BHDS patients, showing
intraparenchymal air-filled spaces surrounded by normal
parenchyma or a thin fibrous wall. Lung tissue adjacent to
the cysts appeared normal. In our patient, we observed
subpleural cysts within the lung parenchyma, formed by
collapsed alveolar walls with a connective tissue lining.
In contrast to the descriptions of other cystic lung
diseases, where a histopathological substrate was present
during pulmonary cystic growth, we found lesions resem-
bling emphysema surrounded by normal lung tissue in this
BHDS case.
MMP behavior has not been previously described in
BHDS. In our pulmonary immunohistochemical analysis,
MMP-9 was expressed in a large number of cells, mostly
macrophages and neutrophils, located in the cyst wall.
However, the lung parenchyma adjacent to the cyst wall
presented only a few scattered MMP-9-positive cells. These
findings suggest that MMP-9, as in other lung cystic
disorders, may be implicated in BHDS cyst development.
Based on the improvement in pulmonary function and the
decrease in urinary and serum MMP-9 levels observed in
our patient, doxycycline, a known inhibitor of tissue MMPs,
may represent a promising therapy for BHDS.
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